Paxlovid-associated rebound is quoted in Nature as occurring in 27% of cases, which is more in line with the anecdata I’ve received than the 5% figures in other research. My anecdata is that it really does hammer down brewing symptoms very effectively, and I haven’t seen reports or systematic trends in the anecdata of the rebound being worse than the first go-’round. So from your perspective, it’s a shot at not getting sick, or maybe of getting less sick.
The risk is yeah, maybe you contribute a miniscule marginal amount to drug resistant COVID-19. The norms of biomedicine are that you, the patient, do not need to concern yourself with that. If the medicine can help you, and your doctor prescribes it, you can have it. You aren’t on the hook to sacrifice the quality of your care for the “greater good.”
Paxlovid-associated rebound is quoted in Nature as occurring in 27% of cases, which is more in line with the anecdata I’ve received than the 5% figures in other research. My anecdata is that it really does hammer down brewing symptoms very effectively, and I haven’t seen reports or systematic trends in the anecdata of the rebound being worse than the first go-’round. So from your perspective, it’s a shot at not getting sick, or maybe of getting less sick.
The risk is yeah, maybe you contribute a miniscule marginal amount to drug resistant COVID-19. The norms of biomedicine are that you, the patient, do not need to concern yourself with that. If the medicine can help you, and your doctor prescribes it, you can have it. You aren’t on the hook to sacrifice the quality of your care for the “greater good.”